Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives.
- Published in:
- Medicinal Research Reviews, 2022, v. 42, n. 2, p. 710, doi. 10.1002/med.21859
- By:
- Publication type:
- Article
Works matching IS 0198-6325 AND VI 42 AND IP 2 AND DT 2022
Results: 11
1
2
Application or function of citric acid in drug delivery platforms.
- Published in:
- Medicinal Research Reviews, 2022, v. 42, n. 2, p. 800, doi. 10.1002/med.21864
- By:
- Publication type:
- Article
3
Haste makes waste: A critical review of docking‐based virtual screening in drug repurposing for SARS‐CoV‐2 main protease (M‐pro) inhibition.
- Published in:
- Medicinal Research Reviews, 2022, v. 42, n. 2, p. 744, doi. 10.1002/med.21862
- By:
- Publication type:
- Article
4
Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases.
- Published in:
- Medicinal Research Reviews, 2022, v. 42, n. 2, p. 946, doi. 10.1002/med.21867
- By:
- Publication type:
- Article
5
Lipidomic landscape in cancer: Actionable insights for membrane‐based therapy and diagnoses.
- Published in:
- Medicinal Research Reviews, 2022, v. 42, n. 2, p. 983, doi. 10.1002/med.21868
- By:
- Publication type:
- Article
6
The antiviral and immunomodulatory activities of propolis: An update and future perspectives for respiratory diseases.
- Published in:
- Medicinal Research Reviews, 2022, v. 42, n. 2, p. 897, doi. 10.1002/med.21866
- By:
- Publication type:
- Article
7
Cell transplantation and secretome based approaches in spinal cord injury regenerative medicine.
- Published in:
- Medicinal Research Reviews, 2022, v. 42, n. 2, p. 850, doi. 10.1002/med.21865
- By:
- Publication type:
- Article
8
Mechanism of activation and the rewired network: New drug design concepts.
- Published in:
- Medicinal Research Reviews, 2022, v. 42, n. 2, p. 770, doi. 10.1002/med.21863
- By:
- Publication type:
- Article
9
A medicinal chemist who reshaped the antiviral drug industry: John Charles Martin (1951–2021).
- Published in:
- Medicinal Research Reviews, 2022, v. 42, n. 2, p. 647, doi. 10.1002/med.21858
- By:
- Publication type:
- Article
10
Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline.
- Published in:
- Medicinal Research Reviews, 2022, v. 42, n. 2, p. 654, doi. 10.1002/med.21856
- By:
- Publication type:
- Article
11
Issue Information.
- Published in:
- Medicinal Research Reviews, 2022, v. 42, n. 2, p. 643, doi. 10.1002/med.21822
- Publication type:
- Article